ASCO 2023 Highlights on the MIRASOL trial in PT-resistant adv. high-grade epithelial Ovarian Cancer
Reporting from ASCO 2023, Rowan Miller discusses practice changing results from the MIRASOL study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian cancer with high folate receptor-alpha expression.
Abstract: LBA5507 - Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression, presented by Kathleen Moore.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/oncology...
Produced by the European Society for Medical Oncology
http://www.esmo.org
Watch video ASCO 2023 Highlights on the MIRASOL trial in PT-resistant adv. high-grade epithelial Ovarian Cancer online without registration, duration hours minute second in high quality. This video was added by user European Society for Medical Oncology (ESMO) 08 June 2023, don't forget to share it with your friends and acquaintances, it has been viewed on our site 1,892 once and liked it 24 people.